'MyBioPharmaSpace'

Island Pharmaceuticals (ASX:ILA) has taken a step forward in the development of its antiviral candidate galidesivir, securing a strategic partnership with the Texas Biomedical Research Institute, one of the world’s most advanced infectious disease centres and a critical player in high-containment pathogen research.

Rossiter previously served as Chief Executive Officer of Genetic Signatures and spent much of her career at Roche, where she held senior roles across Pharmaceuticals, Diabetes Care and Diagnostics.

Mayne Pharma has officially opened its newly expanded manufacturing facility in Salisbury, South Australia, its most significant operational investment in years, just weeks after the collapse of a proposed takeover by US-based Cosette Pharmaceuticals.

The half-yearly update tends to suggest higher spending on pharmaceuticals simply because of the impact of new listing decisions since May. However, it does not include published updated forecasts for pharmaceutical expenditures. It merely states the topline impact of listings since May.

The timing, just days after the announcement of a new US–UK trade agreement, has highlighted the changing global environment for pharmaceutical pricing with the more assertive stance of the Trump administration.

If the industry intends to resist a new statutory pricing framework, which would be fair enough, it must honestly consider what that would look like in practice. Is it prepared to manage the short-term consequences? Is it able to withstand political pressure, public scrutiny, and the effects on its day-to-day dealings with the Government?

Cynata Therapeutics (ASX:CYP) has reached a clinical milestone, completing patient enrolment in its Phase 2 trial of CYP-001, an investigational stem-cell therapy for acute graft-versus-host disease.

Prescient Therapeutics (ASX:PTX) has taken a significant step forward in its oncology pipeline, announcing that European regulators have authorised the company to begin a Phase 2a clinical trial of PTX-100 in patients with relapsed or refractory Cutaneous T-cell Lymphoma

Orthocell (ASX:OCC) has taken an important step in its international expansion plans, submitting a regulatory application to the British Standards Institution seeking approval to commercially distribute its nerve repair device, Remplir, across the European Union and the United Kingdom.

Neuren Pharmaceuticals (ASX:NEU) has secured another significant regulatory milestone in its Rett syndrome program, announcing that partner Acadia Pharmaceuticals has received U.S. FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for oral solution.

Dimerix (ASX:DXB) has reached a significant milestone in its late-stage clinical program, announcing that its global ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis has now completed recruitment and dosing of its target 286 adult patients.

Radiopharm Theranostics (ASX:RAD) has announced encouraging interim results from its U.S.-based Phase 2b clinical imaging trial of RAD 101, reporting that 92 per cent of evaluable patients achieved concordance between RAD 101 PET imaging and MRI, the study’s primary endpoint.